Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Feb 7, 2009; 15(5): 538-551
Published online Feb 7, 2009. doi: 10.3748/wjg.15.538
Published online Feb 7, 2009. doi: 10.3748/wjg.15.538
Table 1 Positive and negative regulators of hepcidin production, signalling pathways involved and human diseases either caused by defective function of the regulatory protein (Hemochromatosis, IRIDA) or inducing activation or suppression of the regulatory pathway
Positive regulators | Signalling pathway | Human disease | Negative regulators | Signalling pathway | Human disease |
Inflammation [IL-6, IL-1α] | STAT-3 | Anemia of chronic disease | Hypoxia [HIF1, sHJV, ROS] | HIF-1, BMPs/SMAD Oxygenases inhibition | -- |
Iron stores [mHJV] | BMPs/ SMAD4 | Hemochromatosis | Iron stores [Matriptase2, s-HJV, GDF15] | BMPs/SMAD inhibition | IRIDA, iron deficiency |
Iron stores [HFE, TfR2] | BMPs/ SMAD4 | Hemochromatosis | Erythropoiesis [GDF15, others?] | BMPs/SMAD inhibition others? | Thalassemia, CDA1 |
Liver metabolic activities | C/EBPα | Erythropoietin? | C/EBPα block | ||
Oxygenases | ? | Oxidative stress [ROS] | C/EBPα, STAT3 block; Oxygenases inhibition HDAC activation | Hepatitis C viral and alcoholic liver disease |
Table 2 Recently published methods for hepcidin quantification in biological fluids
Method | Reported normal range in serum (No. of controls) | Intra-assay precision (CV1) (%) | Internal standard | Note | LLOD2 | Reference |
C-ELISA | 29-254 ng/mL (males) 17-286 ng/mL (females) (n = 114) | 5-19 | n.a. | Also used to quantify hepcidin in urine | 5 ng/mL | Ganz[76], 2008 |
Quantitative SELDI-TOF-MS | 9-45 ng/mL (males) 7-15 ng/mL (females) (n = 23) | 5.7-11.7 | Des-Asp Hepcidin-24 (deletion of aspartate residue at position 25) | Also used to quantify hepcidin in urine | 3 ng/mL | Swinkels[77], 2008 |
Quantitative SELDI-TOF-MS | 50 ng/mL (average in females) (n = 24) | 8-9 | Stable isotope labelled hepcidin (13C/15N phenylalanine at position 9) | 10 ng/mL | Ward[79], 2008 | |
Micro-HPLC tandem tandem MS | 1-19.5 ng/mL (males) 1-6.5 ng/mL (females) (n = 10) | 4.8-21 | Stable isotope labelled hepcidin (13C/15N isoleucines at position 6-8) | 1 ng/mL | Kobold[78], 2008 | |
Liquid Cromatography tandem MS | n.a. | 8.7-12.5 | Stable isotope labelled hepcidin (13C/15N glycines at position 12-20) | Only used in urine for the moment | n.a. | Bansal[75], 2008 |
Hepcidin binding domain based test | 39-88 ng/mL (n = 40) | < 5 | n.a. | Potential for measuring true biologically active hepcidin (e.g. able to bind ferroportin) | n.r. | De Domenico[1], 2008 |
- Citation: Piperno A, Mariani R, Trombini P, Girelli D. Hepcidin modulation in human diseases: From research to clinic. World J Gastroenterol 2009; 15(5): 538-551
- URL: https://www.wjgnet.com/1007-9327/full/v15/i5/538.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.538